PMID- 11694315
OWN - NLM
STAT- MEDLINE
DCOM- 20011219
LR  - 20190826
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 120
IP  - 1-2
DP  - 2001 Nov 1
TI  - Expression of Fas ligand by microglia: possible role in glioma immune evasion.
PG  - 19-24
AB  - The immune-privileged status of the central nervous system is thought to limit 
      the application of immunotherapy for treatment of malignant brain tumors. Because 
      the Fas pathway has been proposed to play a role in immune evasion, we examined 
      the effect of tumor environment on the expression of Fas ligand (FasL) in a mouse 
      glioma model. Immunoblotting revealed the expression of membrane-bound FasL to 
      nearly double when murine G26 gliomas were propagated intracranially (IC) as 
      compared to subcutaneously (SC). Further analysis by flow cytometry revealed 
      microglia, which were absent in the SC tumors, to account for half of the FasL 
      expression in the IC tumors. Interestingly, when FasL activity was inhibited in 
      IC tumors, the proportion of tumor-infiltrating leukocytes increased three-fold, 
      reaching the same frequency as the SC tumors. These observations suggest that 
      microglia are a major source of FasL expression in brain tumors and possibly 
      contribute to the local immunosuppressive milieu of malignant gliomas.
FAU - Badie, B
AU  - Badie B
AD  - Neuro-oncology Laboratory, Department of Neurological Surgery, University of 
      Wisconsin School of Medicine, K3/805 Clinical Science Center, 600 Highland Ave., 
      Madison, WI 53792-3232, USA. badie@neurosurg.wisc.edu
FAU - Schartner, J
AU  - Schartner J
FAU - Prabakaran, S
AU  - Prabakaran S
FAU - Paul, J
AU  - Paul J
FAU - Vorpahl, J
AU  - Vorpahl J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Surface)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (Fasl protein, mouse)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - Antigens, Surface/immunology
MH  - Blood-Brain Barrier/immunology
MH  - Brain Neoplasms/drug therapy/*immunology/metabolism
MH  - Cell Movement/immunology
MH  - Drug Resistance, Neoplasm/*immunology
MH  - Fas Ligand Protein
MH  - Flow Cytometry
MH  - Frontal Lobe/immunology/metabolism/surgery
MH  - Glioma/drug therapy/*immunology/metabolism
MH  - Gliosis/immunology
MH  - Immune Tolerance
MH  - Immunologic Surveillance/*immunology
MH  - Immunosuppressive Agents/*metabolism
MH  - Macrophages/immunology/metabolism/pathology
MH  - Membrane Glycoproteins/antagonists & inhibitors/*immunology/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL/immunology/metabolism/surgery
MH  - Microglia/*immunology/metabolism/pathology
MH  - Treatment Failure
MH  - Tumor Cells, Cultured/immunology/metabolism/transplantation
EDAT- 2001/11/06 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/06 10:00
PHST- 2001/11/06 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/06 10:00 [entrez]
AID - S0165572801003617 [pii]
AID - 10.1016/s0165-5728(01)00361-7 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2001 Nov 1;120(1-2):19-24. doi: 10.1016/s0165-5728(01)00361-7.